¡¸ ºô¸ô¤º¬ìÄ~Äò±Ð¨| ¡¸
¦³®Ä´Á¶¡¡G¥Á°ê 95¦~06¤ë16¤é ¦Ü 95¦~06¤ë30¤é ¤î

    Case Discussion

<Chief complaint>

Intermittent palpitations for one year.

<Case presentation>

     A 19-year-old girl had been healthy before until one year ago when she suffered from intermittent palpitations. The paroxysmal episodes were accompanied by profuse sweating and headache, the duration and frequency of which were about 20-30 minutes and 2-3 times per day, respectively. There was no known precipitating factor. She visited a hospital where hypertension was noted (BP about 170/100 mmHg). Secondary hypertension was impressed, and she underwent serial studies to search the underlying causes.

      Twenty-four-hour urine level of vanillylmandelic acid (VMA) reported 182 £gmole/day (normal < 31). Pheochromocytoma was highly suspected, but both computer tomography of the adrenal glands and 131I-metaiodobenzylguanidine (MIBG) scan were negative. She took doxazosin (1.5 mg Q.D.) and nifedipine if needed but the discomfort was only slightly alleviated. So she visited a medical center for second opinion and was admitted for further evaluation and management.

     She was a student and denied smoking, alcohol consumption, other systemic diseases and a family history of hypertension.

     Physical examination revealed a 63 kg, 163 cm-tall girl without a round face, acne or truncal obesity. Her temperature was 36.9¢XC, pulse rate 76/min, respiratory rate 20 /min and her blood pressure was 160/90 mmHg. Her conjunctivae were pink, sclerae were anicteric and pupils were isocoric with prompt light reflex. Her neck was supple without a goiter, engorged jugular veins, or lymphadenopathy. The thoracic, abdominal, and neurologic examinations were normal. There was no gynecomastia, galactorrhea, buffalo hump or purple striae.

<Laboratory data>

Table1. Endocrine test

Renin

Aldosterone

Cortisol (8AM)

Cortisol (4PM)

DHEA-SO4*

ng/mL/hr
(1-5)

ng/dL
(5-30)

£g g/dL
(5-25)

£g g/dL
(2.5-12.5)

£g mol/L
(4.6-15.4)

6.40

66.75

10.3

6.87

4.7

Table2. 24 HR urine catecholamine

Dopamine

Epinephrine

Norepinephrine

VMA

£g g/24h
(50-450)

£g g/24h
(< 22.4) ƒÝ

£g g/24h
(12.1-85.5)

mg/24h
(1-7)

361.4

15.2

1173.2

18.1

*DHEA-SO4: dehydroepiandrosterone sulfate

<Course and treatment>

     She discontinued all medications for two weeks. Complete blood counts and biochemical studies, including serum electrolytes were within normal ranges. Both 24-hr urine levels of VMA and norepinephrine increased. Other endocrine studies were within normal limits except serum rennin activity and aldosterone level elevated. Computer tomography of chest, abdomen and pelvis revealed a heterogeneous and moderately enhanced mass about 4 cm around the pancreatic head (Fig 1 ). Bilateral adrenal glands were normal in size. Previous 131I-MIBG scan was negative, so she received 2-[Flurine-18] fluoro-2-deoxy-D-glucose positron emission tomography (PET) of whole body. The image showed a large FDG hypermetabolic ring lesion at right sub-hepatic region (Fig 2). She got a magnetic resonance image to exclude vascular invasion. She took phenoxybenzamine for pre-operative blood pressure control and propranolol for tachycardia. She successfully accepted an operation for tumor excision. No vascular invasion was noted. The tumor was soft and well encapsulated and the pathology confirmed the diagnosis of paraganglioma (Fig 3 & 4 ). Post-operative 24-hour urine levels of VMA and norepinephrine decreased apparently. She never had palpitation and hypertension after removal of the tumor and needed no antihypertensive drugs, either. She followed up regularly at OPD.

<Discussion>

       ¤p©ó30·³©Î¤j©ó60·³¥X²{°ª¦åÀ£ªº¯f¤H³£»Ý¦Ò¼{Äòµo©Ê°ª¦åÀ£(secondary hypertension)¡C¶Ý»Ì²Ó­M½F(pheochromocytoma)¬O­ì¦]¤§¤@¡A90¢Hªº¶Ý»Ì²Ó­M½F¦ì©óµÇ¤W¸¢¡A10¢H¦bµÇ¤W¸¢¥~¡AºÙ¬°°Æ¯«¸g¸`½F(paraganglioma)¡A«áªÌ±q¯«¸g¸`ªø¥X¡A¤j³¡¤À¥i¦b¸¡µÄ¤ºµo²{¡A¦ý¤]¥i¥H¦ì©ó«á¸¡µÄ¡B°©¬ÖµÄ¡B«e«áÁa¹jµÄ¡B¤ßŦ©Î¥D°Ê¯ß®Ç¡C³\¦h¯f¤H©ó¶EÂ_«e´N¦]¤ß«ß¤£¾ã©Î¤¤­·¦º¤`¡A¤j¦h¼Æªº¯f¤H³£¦³°ª¦åÀ£¡BÀYµh¡B¤ß±ª¤Î«_¦½µ¥¯gª¬¡C15¢Hªº¶Ý»Ì²Ó­M½F¬O´c©Êªº¡A¥i¥HÂಾ¨ìÀY°©¡B¦Ø°©¡B¯á´Õ¡B¯ÝºÞ¡B¸zô½¤©MªÍŦ¡F°Æ¯«¸g¸`½Fªº´c©Ê¾÷·|¸û°ª¡A¬ù30-50¢H¡C¤j¬ù30-60¢Hªº°Æ¯«¸g¸`½F¬O¦³¥\¯àªº(functional)¡A¥i¥H¤Àªcnorepinephrine¤Înormetanephrine¡A¦ý¬O¨Ã¤£·|¦]¦¹¼vÅT¥Í¦s¡C

      °£¤FÁ{§É¯gª¬¥~¡A¤´»Ý¥Í¤ÆÀˬd»²§U¶EÂ_¡A¦p¦å¼ß©M§¿²G¤¤ªºcatecholamines¤Îmetanephrine (catecholamineªº¥NÁª«)¡C¥Ø«e¥H´ú§¿²G¤¤ªºmetanephrineªº±Ó·P©Ê³Ì°ª¡A¦ý¬O°ò©ó¹êÅç«Çªº­­¨î¡A§Ú­Ìªº¯f¤H¥u´ú¤G¤Q¥|¤p®É§¿²G¤¤ªºVMA¤Îcatecholamines¡CµM¦Ó¡A¦³¨ÇÃĪ«¡B­¹ª«(©@°Ø¦]¡B­»¿¼)¡B©Î¯e¯f¤]³£·|¼vÅT¦å¼ß©Î§¿²Gcatecholaminesªº¿@«×¡AÄ~¦Ó¤zÂZ§Ú­Ìªº¶EÂ_¡A©Ò¥HÀ³¸Ó¥J²Ó°Ý¶E¡A¦pªG¤¹³\¡A©óÀˬd«eÀ³°±¤î©Ò¦³ÃĪ«¦Ü¤Ö¨â¬P´Á¡C¤]¥i¥H´úserum chromogranin A (CgA)¡A¥¿±`±¡ªp¤U¡ACgA¦­¤W¤KÂI®É¦å¤¤¿@«×³Ì§C¡A¤U¤È¤Î±ß¤W11ÂI®É¿@«×³Ì°ª¡A¥BCgAªº¿@«×©M¸~½F¤j¤p¦³Ãö¡A©Ò¥H¬O¤@­Ó¦³¥Îªº¸~½F¼Ð»x¡C¦]¬°catecholamines¥i¥H«P¶irenin¤Àªc¡A©Ò¥H¦³¨Ç¯f¤H¦å¤¤ªºrenin¤Îaldosterone¤]·|¤W¤É¡A¦p¦P§Ú­Ìªº¯f¤H¡C

     Á{§É¤W§Q¥Îmetaiodobenzylguanidine (MIBG) scans©M¹q¸£Â_¼hÀˬd¨Ó©w¦ì¡CMIBGªº±Ó·P©Ê¬ù85¢H¡A¦ý¬O¹ï©ó°»´úµÇ¤W¸¢¥~¸~½F®É±Ó·P©Ê·|¤U­°¡C§Ú­Ìªº¯f¤H©óÁ{§É¤W(¥]¬A¯gª¬¤ÎÀËÅç)±j¯PÃhºÃ¬O¶Ý»Ì²Ó­M½F¡A¦ý¬OµÇ¤W¸¢¹q¸£Â_¼hÀˬd¤ÎMIBG«o¨S¦³§ä¨ì¸~½F¡A¦¹®É´N­n¦Ò¼{°Æ¯«¸g¸`½F¡A¦]¦¹¶·¦h§@¯ÝµÄ¡B¸¡µÄ¤Î°©¬ÖµÄ¹q¸£Â_¼h¡C©ó¹q¸£Â_¼hÀˬd«e¡A¤@©w­n¥ý±±¨î¦åÀ£¡A¦]¬°Åã¼v¾¯·|³y¦¨°ª¦åÀ£¦M¶H¡CÃh¥¥¯f¤H­º¿ïªºÀˬd¬O®ÖºÏ¦@®¶³y¼v¡A¦]¬°¤£»Ý­n¥´Åã¼v¾¯¡A¤]¨S¦³¿ç®g½u¡F¥[§@¦åºÞÄá¼v¥i¥Hª¾¹D¬O§_¦³¦åºÞ«I¥Ç¡C¥¿¤lÄá¼v(positron emission tomography¡APET)¹ï©w¦ì´c©Ê¶Ý»Ì²Ó­M½FÂಾªº±Ó·P©Ê¤£¿ù¡A¦ý¬O¯S²§©Ê¸ûMIBG®t¡A¦n³B¬O¥i¥H¥ß§Y§@¤£»Ý¨Æ«e·Ç³Æ¡C

     ªvÀø¥H¤â³N¤Á°£¬°¥D¡A¤ºµøÃèµÇ¤W¸¢¤Á°£(laparoscopic adrenectomy)¬O¥Ø«eªº¥D¬y¡CµM¦Ó­n°µ¦n³N«e·Ç³Æ¡A¥H¨¾°ª¦åÀ£¦M¶H©Î¥ð§J¡F«Øij¨Ï¥Î£\-blockers(¦pphenoxybenzamine¡Bdoxazosin©Îprazosin)¡A¦ý¬O·|¼W¥[catecholamines©Mmetanephrineªº¦X¦¨¡A¨Ï±o¤ß¸õ¥[§Ö¡A¦¹®É¥i¥H¨Ö¥Î£]- blockers¡A¹ïªvÀøÁy³¡¼é¬õ¤]¦³®Ä¡C¦³¨Ç±M®a«Øij¨Ï¥Î¶tÂ÷¤lªýÂ_¾¯¡A¦]¬°³N«e¤ô¥÷¤£»Ý­n¸É¥R¤Ó¦h¥B¯f¤Hªº­@¨ü©Ê¸û¦n¡C¥Ñ©ócatecholamines·|¨ë¿Erenin¤Àªc¥B¸~½F²Ó­M¤W¦³angiotensin-coverting enzyme (ACE)ªºµ²¦X¦ì¸m¡A©Ò¥H¥i¥H¦P®É¨Ï¥ÎACE inhibitors©Îangiotensin receptor blockers (ARBs)¡A¦ý¬O¥¥°ü¸T¥Î¡A¦]¬°·|­P·î­L¡C

     ¸~½F¤Á°£«á¤´¦³25¢Hªº¯f¤H·|¦³°ª¦åÀ£¡C¨}©Ê¶Ý»Ì²Ó­M½F5¦~¦s¬¡²v¬°96¢H¡A´c©Ê¸~½F¥u¦³44¢H¡C¤â³N«á2¬P´Á¦A°lÂܧ¿²Gcatecholamines¤Îmetanephrine¡A¤§«á¤]­n©w´Á°lÂÜ¡C

<References>

  1. Kebebew E, Duh QY: Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. Surg Oncol Clin N Am 1998;7:765.
  2. Lenders JW et al: Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427.
  3. Lenz T et al: Diagnosis of pheochromocytoma. Clin Lab 2002;48:5.
  4. Roelants V et al: Iodine-131-MIBG scintigraphy in adults: interpretation revisited ? J Nucl Med 1998 ;39 :1007.
  5. Hoegerle S et al: Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 2002;222:507.
  6. Combemale F et al: Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and peri-operative management of pheochromocytoma. 70 cases. Ann Chir 1998;52:341.
  7. Winfield HN et al: Technique of laparoscopic adrenalectomy. Urol Clin North Am 1997;24:459.
  8. Tagaya N et al: Laparoscopic resection of a functional paraganglioma in the organ of Zucherkandl. Surg Endosc 2002;16:219.

Ä~Äò±Ð¨|¦ÒÃD
1.
(E)
­þ¨Ç¯f¤H»Ý­nÃhºÃ¬OÄòµo©Ê°ª¦åÀ£¡H
A ¦~¬ö¤p©ó30·³
B ¦~¬ö¤j©ó60·³
C °ª¦åÀ£«ÜÃø¥ÎÃĪ«±±¨î
D ¨S¦³¨Ï¥Î¥ô¦óÃĪ«¦ý¬O¥X²{§C¦å¹[
E ¥H¤W¬Ò¬O
2.
(C)
¤U¦C¦óªÌ¹ï©ó¶EÂ_¶Ý»Ì²Ó­M½Fªº±Ó·P©Ê³Ì°ª¡H
A urine norepinephrine
B urine epinephrine
C urine metanephrine
D urine VMA
E urine dopamine
3.
(B)
¤U¦C¦³Ãö¶Ý»Ì²Ó­M½Fªº±Ô­z¦óªÌ¥¿½T¡H
A 90¢Hªº¶Ý»Ì²Ó­M½F¦ì©óµÇ¤W¸¢¥~
B °Æ¯«¸g¸`½F¤]¥i¥H¦ì©ó«á¸¡µÄ
C µÇ¤W¸¢¤º¸~½F´c©Ê¾÷·|¸û°ª
D ¥u¦³¤Ö¼Æªº¯f¤H¦³¯gª¬
E ·|¤Àªccatecholaminesªº°Æ¯«¸g¸`½F¨Ï±o¯f¤H¹Ø©R¸ûµu
4.
(D)
¤U¦C¦óªÌ¤£·|¼W¥[catecholamine±Æªn¡H
A Banana
B Caffeine
C Bronchodilators
D Renal failure
E Cocaine
5.
(A)
¦³Ãö¶Ý»Ì²Ó­M½Fªº©w¦ì¡A¤U¦C¦óªÌ¬O­º¿ïªº¼v¹³Àˬd¡H
A 131I-MIBG scan
B MRI
C PET
D somatostatin receptor imaging
E MRI & MRA
6.
(C)
±j¯PÃhºÃ¬O¶Ý»Ì²Ó­M½F¡A¦ý¬OµÇ¤W¸¢¹q¸£Â_¼h¤ÎMIBG scanµL²§±`®É¤U¤@¨BÀ³¸Ó¦p¦ó¡H
A §@®ÖºÏ¦@®¶Äá¼v
B §@¥¿¤lÄá¼v
C ¥[§@¯Ý¡B¸¡¤Î°©¬ÖµÄ¹q¸£Â_¼h
D ÃĪ«ªvÀø
E somatostatin receptor imaging
7.
(D)
¦ó³Bªº°Æ¯«¸g¸`½F´c©Ê¾÷·|¸û°ª¡H
A µÇŦ©P³ò (perinephric)
B °©¬ÖµÄ(pelvis)
C ¤ßŦ(heart)
D «á¸¡µÄ(retroperitoneal)
E «eÁa¹jµÄ(anterior mediastinum)
8.
(E)
¤U¦C¦ó³B¥i¥H¥X²{°Æ¯«¸g¸`½F¡H
A ¤ßŦ
B «áÁa¹jµÄ
C ³±¹D
D »H¯Ö
E ¥H¤W¬Ò¥i
9.
(B)
¤U¦C¦óªÌÃĪ«¬O±±¨î¶Ý»Ì²Ó­M½F¬ÛÃö°ª¦åÀ£ªº­º¿ï¡H
A propranolol
B phenoxybenzamine
C nicardipine
D irbesartan
E furosemide
10.
(A)
¤U¦C±Ô­z¦óªÌ¦³»~¡H
A °Æ¯«¸g¸`½F¤Á°£«á©Ò¦³¯f¤Hªº¦åÀ£³£¥i¥H«ì´_¥¿±`
B ¤â³N¤Á°£¸~½F2¬P´Á«á¦A´ú§¿²Gcatecholamines¿@«×
C CgA¥i¥H§@¬°³N«á°lÂÜ«ü¼Ð
D °Æ¯«¸g¸`½F¥i¥H«I¥Ç©PÃä²Õ´
E ¨}©Ê¸~½F¤Á°£«á5¦~¦s¬¡²v«Ü°ª

µª®×¸ÑªR 

  1. ¡iE¡jA diagnosis of secondary hypertension should be considered in the following situations: (1) age at onset younger than 30 or older than 60 years, (2)hypertension that is difficult to control after therapy has been initiated, (3) stable hypertension that becomes difficult to control, (4)clinical occurrence of a hypertensive crisis, and (5) the presence of signs or symptoms of a secondary cause such as hypokalemia or metabolic alkalosis that is not explained by diuretic therapy.
  2. ¡iC¡j¥Ø«e¥H´úurine metanephrine¤§±Ó·P©Ê³Ì°ª¡C
  3. ¡iB¡j(A)10¢Hªº¶Ý»Ì²Ó­M½F¦ì©óµÇ¤W¸¢¥~ (C)µÇ¤W¸¢¥~¸~½F´c©Ê¾÷·|¸û°ª (D)¤j¦h¼Æªº¯f¤H³£¦³°ª¦åÀ£¡BÀYµh¡B¤ß±ª¤Î«_¦½µ¥¯gª¬ (E)¦³¨Ç°Æ¯«¸g¸`½F¥i¥H¤Àªcnorepinephrine¤Înormetanephrine¡A¦ý¬O ¨Ã¤£·|¦]¦¹¦Ó¼vÅT¥Í¦s¡C
  4. ¡iD¡jRenal failure decreases catecholamine excretion.
  5. ¡iA¡jÁ{§É¤W¥D­n¨Ï¥Î131I-MIBG scans¨Ó©w¦ì¶Ý»Ì²Ó­M½F¡Abenzylquanidine¬Oquanethidineªº­l¥Íª«¡A¬O¤@ºØ°²©Ê¯«¸g¶Ç¾Éª«½è¡A·|²Ö¿n¦b¤Àªccatecholamineªº²Ó­M¤¤¡C
  6. ¡iC¡j±j¯PÃhºÃ¬O¶Ý»Ì²Ó­M½F¦ý¬OµÇ¤W¸¢¹q¸£Â_¼hÀˬd¤ÎMIBG«o¨S¦³§ä¨ì ¸~½F®É¡A´N­n¦Ò¼{°Æ¯«¸g¸`½F¡A¦]¦¹¶·¦h§@¯Ý¡B¸¡¤Î°©¬ÖµÄ¹q¸£Â_¼h¡C
  7. ¡iD¡jRetroperitoneal paragangliomas are more likely to be malignant.
  8. ¡iE¡j¥H¤W¬Ò¥i
  9. ¡iB¡j £\-blockers(¦pphenoxybenzamine¡Bdoxazosin©Îprazosin)¬OªvÀø¶Ý»Ì ²Ó­M½F°ª¦åÀ£ªº­º¿ï¡C
  10. ¡iA¡j(A)§Y¨Ï¸~½F¤Á°£«á¡A¤´¦³25¢Hªº¯f¤H·|¦³°ª¦åÀ£¡A»Ý­nÃĪ«ªvÀø¡C (B)§Y¨Ï¤Á°£¸~½F10¤Ñ©Î§ó¤[«á¡A¤´¥i¥H¦b¦å²G¤Î§¿²G¤¤´ú±o°ª¿@«×ªº catecholamines¡A¦]¦¹«Øij³N«á2¬P´Á¦A°lÂÜ¡C(C) CgAªº¿@«×©M¸~½F¤j¤p¦³Ãö¡A©Ò¥H¬O¤@­Ó¦³¥Îªº¸~½F¼Ð»x¡A¨ä±Ó·P©Ê¬°83-90¢H¡A¦Ó¯S²§©Ê¬°96¢H¡C(D)Paragangliomas can be locally invasive (E) ¨}©Ê¸~½F¤Á°£«á5¦~¦s¬¡²v96¢H¡C


Top of Page